Clinical trials: Type 1 Diabetes, completed
Diabetes Mellitus, Type 1
A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements
This study will look into how a base dose of insulin peglispro and insulin glargine will affect the meal time dose and efficacy of insulin lispro in type 1 diabetics.
- Trial name
- NCT02152384
- Testing
- Insulin Peglispro, Insulin Lispro, Insulin Glargine
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Impact of Different Types of Exercise Training on Biochemical Markers of Insulin-dependent Patients
Background: Type 1 diabetes mellitus (T1DM) is characterized by the destruction of β cells and consequent loss of insulin secretion due an autoimmune process, being associated with increased cardiovascular risk, oxidative stress…
- Trial name
- NCT02939768
- Testing
- High-intensity interval training (HIIT), Strength training (ST), ST combined with HIIT (ST+HIIT)
- Where
- Brazil
- Volunteers
- 28 people
- Sponsor
- Federal University of Rio Grande do Sul
Diabetes Mellitus, Type 1, Periodontal Diseases
Periodontal and Salivary Evaluation of Type 1 Diabetes Mellitus Patients
Diabetes Mellitus is a risk factor for periodontal disease increasing its prevalence, extension and severity. Periodontal disease is considered the sixth complication of diabetes.
- Trial name
- NCT02935868
- Where
- Brazil
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Diabetes Mellitus, Type 1
Assess the Impact of Insulclock on Glycemic Variability and Treatment Compliance in Uncontrolled DM1 Patients
Insulclock® is a small electronic device developed to facilitate the optimal administration of insulin. This device works as an add-on module of commercially available insulin pens and monitors the date, time and dose of…
- Trial name
- Segoclock2 (NCT04847778)
- Testing
- Use of Insulclock system, both Insulclock device and Insulclock 360 app., Use of Insulclock system, both Insulclock device and Insulclock app on masked mode.
- Where
- 4 sites in Spain
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Hospital General de Segovia
Diabetes Mellitus, Type 1
Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus
Insulin lispro is approved by the Food and Drug Administration (FDA) for the treatment of diabetes mellitus. Recombinant human hyaluronidase (rHuPH20) is approved by the FDA as an aid to the absorption and dispersion of other…
- Trial name
- NCT00883558
- Testing
- Insulin Lispro, regular human insulin, recombinant human hyaluronidase PH20
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Halozyme Therapeutics
Incretin Effect
Quantification of the Incretin Effect in Healthy Subjects and Patients With Type 2 Diabetes
Patients with T2DM lac a sufficient incretin response after oral glucose intake. It has only been tested using 50g of glucose. We don't know if patients with T2DM are capable of regulating the incretin effect like healthy people…
- Trial name
- NCT00529048
- Testing
- Oral Glucose Tolerance Test, Isoglycemic clamp, Gastric emptying rate
- Where
- Denmark
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Herlev Hospital
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this clinical trial is to evaluate the variability in the blood glucose-lowering effect of NN1250 (insulin degludec) in subjects with type 1 diabetes.
- Trial name
- NCT00961324
- Testing
- insulin degludec, insulin glargine
- Where
- Germany
- Volunteers
- 54 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, Hypoglycemia
Cognitive Function and Electrocardiogram (ECG) During Hypoglycemia and Blockade of the Renin-angiotensin System
Hypothesis: Treating patients with type 1 diabetes with a certain antihypertensive drug preserve cerebral function during hypoglycaemia.
- Trial name
- NCT01116180
- Testing
- Angiotensin II receptor antagonists (Candesartan)
- Where
- Denmark
- Volunteers
- 9 people
- Sponsor
- Louise Faerch
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Telemedicine Continuous Remote Monitoring of Adults With Uncontrolled Diabetes Mellitus
The purpose of this single center observational study is to determine the effect of continuous remote continuous glucose monitor (CGM) reporting coupled with a telemedicine intervention (Tele-CGM program) on levels of HbA1C in…
- Trial name
- TELEMTRRDM (NCT05161793)
- Testing
- Tele-Monitor DM
- Where
- United States
- Volunteers
- 230 people
- Sponsor
- University of Southern California
Diabetes Type I, Diabetes Type II
Feasibility Study of DermGEN for Diabetic Foot Ulcer Treatment
The purpose of this clinical trial is to perform a limited pilot study to determine the safety and feasibility of DermGEN in the treatment of non-healing diabetic foot ulcers (DFU). This will be a one-arm prospective study.
- Trial name
- NCT02184455
- Testing
- DermGEN
- Where
- 2 sites in Canada
- Volunteers
- 11 people
- Sponsor
- Dr. Paul F. Gratzer
Diabetes, Diabetes Mellitus, Type 1
Paediatric Subjects - Special Survey
This study is conducted in Japan. The aim of this study is to collect safety and efficacy data when using insulin aspart in children with diabetes under normal clinical practice conditions.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01538576
- Testing
- insulin aspart
- Where
- Japan
- Volunteers
- 71 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Steno Tech Explore: A Study of Insulin Pump Users With Type 1 Diabetes
The present study is part of an overarching study being conducted in Denmark at Steno Diabetes Center Copenhagen (SDCC) and Nordsjællands Hospital Hillerød (NOH), Steno Tech, that aims to develop and ultimately, in a randomized…
- Trial name
- NCT04311164
- Testing
- Questionnaire-based survey, No intervention given.
- Where
- 2 sites in Denmark
- Volunteers
- 770 people
- Sponsor
- Steno Diabetes Center Copenhagen
Type 2 Diabetes Mellitus
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, Following Subcutaneous Administration in Healthy Volunteers
ZYD1 is a novel GLP-1 receptor agonist. The ZYD1 exhibits increased stability to proteolytic cleavage, especially against dipeptidyl peptidase-4 (DPP-IV). ZYD1 is a potent antidiabetic agent without gastrointestinal side-effects.
- Trial name
- ZYD1 (NCT01972893)
- Testing
- ZYD1
- Where
- India
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Zydus Lifesciences Limited
Type 1 Diabetes Mellitus
Screening of Subjects With Type I Diabetes to Determine Eligibility for Islet Transplantation
Protocol to screen potential subjects for islet transplantation
- Trial name
- NCT02004964
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Rodolfo Alejandro
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes
Sphingolipids are associated with metabolic diseases. Distribution of plasma sphingolipids in type 1 and type 2 diabetes has never been studied.
- Trial name
- CERADIAB (NCT03447964)
- Testing
- dosing of sphingolipids
- Where
- France
- Volunteers
- 128 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Diabetes Mellitus, Type 1
A Study in Adults With Type 1 Diabetes
The purpose of this study is to compare the effectiveness and safety of LY2963016 versus Lantus when taken once daily in combination with insulin lispro before meals three times a day.
- Trial name
- ELEMENT 1 (NCT01421147)
- Testing
- LY2963016, Lantus, Insulin Lispro
- Where
- 52 sites in United States, Belgium and 7 more
- Volunteers
- 536 people
- Sponsor
- Eli Lilly and Company
Diabetic Nephropathy
Effect of Pyridorin in Patients With Diabetic Nephropathy
The primary objective of the study is to evaluate the safety, tolerability and efficacy of Pyridorin (pyridoxamine dihydrochloride) up to 250 mg given orally twice daily in patients with diabetic kidney disease.
- Trial name
- NCT00320021
- Testing
- Pyridorin (pyridoxamine dihydrochloride)
- Volunteers
- 80 people
- Sponsor
- BioStratum
Type 1 Diabetes Mellitus
Islet Transplantation Using Abatacept
Islet transplantation in type 1 diabetics with hypoglycemic unawareness using abatacept as a part of a novel calcineurin-inhibitor-sparing immunosuppressive regimen.
- Trial name
- NCT00276250
- Testing
- Efalizumab, Abatacept, Belatacept
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Diabetes Mellitus Type 1
Comparison of Basal (Fasting) Glycemic Control in Type 1 Diabetic Patients With CSII Achieved by the Circadian Slide Ruler Scale or Flat Basal Rate
This is a pilot trial to establish study procedures that allow comparison of various starting basal rate profiles used in Continuous Subcutaneous Insulin Infusion (CSII).
- Trial name
- NCT00569452
- Testing
- Accu-Chek Spirit Insulin Pump
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche
Caffeine and Carbohydrate, Carbohydrate Only
Caffeine Ingestion to Counter the Exercise-mediated Fall in Glycaemia in Type 1 Diabetes
This project will aim to investigate the clinical efficacy and metabolic effects of a pre-exercise dose of caffeine with a low (10g) dose of carbohydrate (CAF+lowCHO) without modification of insulin degludec on exercise…
- Conditions
- Caffeine and Carbohydrate, Carbohydrate Only, Placebo
- Trial name
- DE-CAF (NCT04671043)
- Testing
- Caffeine and glucose, Glucose alone
- Where
- Switzerland
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.